

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-13. (cancelled)

14. (currently amended) A DNA transfer vector comprising [[a]] at least one of the nucleotide sequences selected from the group consisting of SEQ ID NO: ~~1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, and 14.~~

15. (previously presented) The DNA transfer vector according to claim 14, wherein said vector is a plasmid.

16. (currently amended) The DNA transfer vector of according to claim 15, further comprising a transcription promotor.

17. (currently amended) The DNA transfer vector of according to claim 16, wherein the transcription promotor is CMV.

18. (currently amended) The DNA transfer vector of according to claim 15, further comprising 4 CpG motifs.

19. (currently amended) The DNA transfer vector of
according to claim 18, ~~further~~ comprising 8 CpG motifs.

20. (previously presented) A pharmaceutical composition comprising a DNA transfer vector according to claim 14 in admixture with pharmaceutically acceptable vehicles and excipients.

21. (previously presented) The pharmaceutical composition according to claim 20, wherein said composition is in a form for parenteral administration.

22. (cancelled)

23. (withdrawn - currently amended) A combined pharmaceutical preparation comprising at least two different DNA transfer vectors according to claim 14, ~~for simultaneous, sequential or separate therapeutic use.~~

24-26. (cancelled)

27. (new) The DNA transfer vector according to claim 14, comprising the nucleotide sequence of SEQ ID NO: 2.

28. (new) The DNA transfer vector according to claim 14, comprising the nucleotide sequence of SEQ ID NO: 12.

29. (new) The DNA transfer vector according to claim 14, comprising the nucleotide sequence of SEQ ID NO: 13.

30. (new) The DNA transfer vector according to claim 14, comprising the nucleotide sequence of SEQ ID NO: 14.